PEAR-GLIO
Research type
Research Study
Full title
Prospective Evaluation of AI R&D tool for Biology and Response in Adult Interventional Neuro-oncology (PEAR-GLIO)
IRAS ID
318531
Contact name
Matt Williams
Contact email
Sponsor organisation
Ourotech Limited (trading as Pear Bio)
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Brain tumours are the leading cause of cancer death in the under 40's, and there has been little progress in the last 15 years. Pear Bio have developed a diagnostic test that may help oncologists decide on the appropriate course of treatment for patients with cancer. The diagnostic test uses a small tumour sample taken from the patient, alongside a blood sample. Samples are placed in a 3D hydrogel to create microtumours, which act as a proxy for the patient to test treatment options in a laboratory without exposing the actual patient to those treatments. Various approved treatment options are tested in parallel microtumours at Pear Bio's central laboratory. A report is generated on which treatments work best on a given patient's tumour sample, so their oncologist can prescribe an effective treatment.
As Pear Bio's technology is still in early development for brain tumours, this study will serve to validate the technology. Tumour and blood samples are taken from patients during standard-of-care surgery and used to optimise Pear Bio's technology to test FDA approved therapies used to treat brain cancers. This study will enable future studies that are used to guide treatment decisions between multiple approved treatment options on a personalised basis. Outside of sample collection during surgery, this is a laboratory-based study designed to optimise various aspects of Pear Bio's technology for primary solid brain tumours, including treatment administration in the Pear Bio system.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
23/NW/0119
Date of REC Opinion
19 May 2023
REC opinion
Further Information Favourable Opinion